Posted inCardiology Internal Medicine news
Oral NLRP3 Inhibition With Ruvonoflast Produces Rapid, Reversible Suppression of Residual Inflammation in Adults at High Cardiovascular Risk
In a Phase 1b placebo-controlled trial, ruvonoflast markedly reduced hsCRP, IL-6, and fibrinogen over 28 days in adults with obesity, elevated hsCRP, and cardiometabolic risk, supporting further evaluation of oral NLRP3 inhibition in atherosclerotic prevention.